The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation
Notably, it resulted in the inhibition of angiogenesis, a crucial process implicated in MS pathology, and concurrently led to a reduction in levels of angiopoietin 2, a protein associated with vascular remodeling and inflammation (MacMillan and Furlong 2012)
It works by reducing oxidative stress and influencing melanin production, which can affect skin tone and clarity
Abundant glutathione levels will off-set the effects of this inflammation at the cellular level
Dosage Protocols Since BPC-157 is not FDA-approved for human use, there are no officially established dosing guidelines
Comprising Delta Sleep-Inducing Peptide, DSIP Vials are intended for research purposes only